anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a method of treating an individual having a TNF-mediated disease comprising administering to the individual multiple doses of an anti-TNF antibody wherein the second or subsequent dose is administered during or immediately prior to relapse of the disease. Preferably, the disease is a TNF.alpha.-mediated disease, such as rheumatoid arthritis. The anti-TNF  antibody can be a monoclonal antibody or fragment thereof, such as a murine antibody, chimeric antibody or a humanized antibody or fragment thereof.  Preferably, the antibody binds to one or more amino acids of human TNF.alpha.  (hTNF.alpha.) selected from the group consisting of 87-108 and 59-80. The antibody can bind to the epitope of A2 or cA2. In a preferred embodiment, the antibody is A2 or cA2.
The vascular endothelium tonically releases nitric oxide that produces smooth muscle relaxation, inhibition of platelet aggregation, and inhibition of cellular proliferation. Studies in the Cardiology Branch have demonstrated that nitric oxide activity is reduced in the coronary and peripheral vasculature of patients with atherosclerosis and in those with risk factors for atherosclerosis. Bradykinin, an endothelium-dependent vasodilator, may be an important modulator of vascular tone in vivo because it is tonically produced by the endothelium. Bradykinin is inactivated by angiotensin converting enzyme (ACE) that is found on the endothelial cell surface. The activity of plasma ACE is variable among individuals and is at least partly genetically determined. ACE activity may modulate the local vascular effects of bradykinin, and thus, ACE inhibitors would be expected to improve endothelium-dependent responses in patients with higher tissue ACE activity.

This protocol is designed to determine 1) the role of bradykinin in stimulating nitric oxide release in the human coronary and peripheral vasculature; 2) whether ACE inhibitors improve bradykinin-induced vasodilation, and if so, whether this occurs as a result of endothelium-dependent release of nitric oxide; 3) whether ACE inhibitors improve the abnormal shear-induced coronary vasodilation in patients with normal coronary arteries and those with coronary artery disease; 4) whether ACE inhibitors and bradykinin affect platelet function; 5) whether the vascular responses to ACE inhibition and bradykinin depend on the ACE genotype.
The invention relates to an external applied medicine for treating beriberi. The external applied medicine consist of the following Chinese herbal medicines in percentage by weight: 15 to 35 percent of glabrous greenbrier rhizome, 15 to 35 percent of yellowmouth dutchmanspipe root, 10 to 25 percent of trifoliate jewelvine root, 10 to 20 percent of Chinese gall and 7 to 15 percent of borax. The external applied medicine is developed through improvement on a descendant nostrum preparation and many years of clinical trials. The external applied medicine is an external applied ointment for treating beriberi and a pure Chinese medicinal preparation, and has the radical treatment effect on multiple kinds of beriberi. After seven days of use, beriberi can be cured and prevented from relapsing within three months. The external applied medicine has the good effect of pain relief, stop of pus and blood, sterilization, antitoinflammatory, antivirus, removal of putrefaction and promotion of tissue regeneration, and enhancement of immunocyte function; moreover, and the external applied medicine is easy to prepare and low in cost, has the excellent effect, and is applicable for industrial processing and production.
The invention relates to a method for producing the complex of the biologically active substances with hypoazotemic, hepatoprotective, antioxidant, and anti-inflammatory activities comprising the extraction of the ground herbal raw material with ethanol, the evaporation to aqueous rest, the purification with chloroform followed by the drying. The leaves of the black locust are used as the starting material. For the extraction, 12 volumes of 29-31% ethanol are used for 13-15 hours. Upon the evaporation at the temperature of 65 ºС, aqueous rest is settled for 12 hours and filtered. Chloroform is added four times at a aqueous layer : chloroform ratio of 2:1. The method can be used for obtaining the active ingredient for developing the drugs intended for treating the diseases of kidneys and liver. The drugs, which may be produced in various dosage forms, are advantageous for long-term use due to the mild effects, the lack of the toxicity and the side effects.
Medication based on physician prescriptions or overcounter use not germane to the study. Subjects also receive physical therapy for 2 weeks.
Toxoplasmic encephalitis is a major cause of illness and death in AIDS patients. Standard treatment for toxoplasmic encephalitis is to combine pyrimethamine and sulfadiazine. Continuous treatment is necessary to prevent recurrence of the disease, but constant use of pyrimethamine/sulfadiazine is associated with toxicity. Clindamycin has been shown to be effective in treatment of toxoplasmic encephalitis in animal studies. This study evaluates pyrimethamine as a preventive treatment against toxoplasmic encephalitis (per 3/26/91 amendment, clindamycin arm was discontinued).

Patients are randomized to receive pyrimethamine or placebo three times a week. All patients must be on aerosolized pentamidine, trimethoprim / sulfamethoxazole (T/S), or dapsone for Pneumocystis carinii pneumonia prophylaxis. Patients will be evaluated bi-weekly for the first month and every other month thereafter for at least 24 months.
BACKGROUND: Inguinal endometriosis is one of the most common forms of endometriosis. The present study introduces 8 cases of inguinal endometriosis and discusses probable theories of inguinal endometriosis by reviewing the literature.
CASE PRESENTATION: 8 Iranian cases of inguinal endometriosis with a mean age of 36 years were presented. Catamenial groin pain and swelling were the most common complications. Also, patients usually had accompanying symptoms such as pelvic pain and dysmenorrhea. One-half of patients had a history of previous abdominal surgery. Ultrasound was diagnostic in 4 patients (50%), and magnetic resonance imaging was used in two patients (25%). Among 6 patients who underwent hormonal therapy, 4 experienced an endometriosis size increase. Inguinal endometriosis was right-sided in 87.5% of patients, and among 4 patients who underwent surgery, 75% had proximal site involvement of the round ligament.
CONCLUSION: According to the rarity of inguinal endometriosis, it is more likely to be a misdiagnosis with other inguinal disorders such as inguinal hernia. Inguinal endometriosis should be considered in patients who undergo inguinal herniorrhaphy, with suspected findings such as thickening of the hernia sac wall, bloody fluid inside the sac, or thickening of the extraperitoneal round ligament during the surgery.
PURPOSE OF THE REVIEW: With the increasing prevalence of cesarean section globally, the importance of perioperative analgesia for cesarean section is becoming increasingly evident. This article provides an overview and update on the current status of cesarean section worldwide and associated analgesic regimens.
RECENT FINDINGS: Some recent studies unveiled potential association of neuraxial analgesia might be associated with children's autism, pharmacologic analgesia in obstetric will potentially gain some more attention. Various commonly used techniques and medications for analgesia in cesarean section are highlighted. While neuraxial administration of opioid remains the most classic method, the use of multimodal analgesia, particularly integration of nonsteroidal anti-inflammatory drugs, acetaminophen, peripheral nerve blocks has provided additional and better options for patients who are not suitable for intrathecal and neuraxial techniques and those experiencing severe pain postoperatively. Optimal pain management is crucial for achieving better clinical outcomes and optimal recovery, and with the continuous development of medications, more and better pharmacologic regimen will be available in the future.
<P>PROBLEM TO BE SOLVED: To provide a system for predicting the relevance ratio of a research gene product by which a relevant network display is available by superimposing expression data on the gene-related network obtained by document data mining by selecting a gene expressed from expression experiment data.  <P>SOLUTION: A document mining database 6 is prepared by applying document mining to a gene database 1, a drug database 2, and a disease database 3. Data indicative of a relation between the disease and the gene, a relation between the drug and the gene, and a relation between genes is prepared and stored on the document mining database 6. Meanwhile, DNA (Deoxyribonucleic Acid) expression information obtained by drug administration is stored on a DNA expression database 7. Document mining data and DNA expression data are integrated and displayed by merging document mining data in the document mining database 6 with data in the DNA expression data base 7 (S3).  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The intervention will be the same for each of the six intervention sessions. The participant will recite to the psychologist the narrative they previously composed for 10-20 min. The psychologist will congratulate the participant for having succeeded in this task and advise them they are finished for the day.
Angiotensin-converting enzyme 2 receptors (ACE2R) are requisite to enter the host cells for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). ACE2R is constitutive and functions as a type I transmembrane metallo-carboxypeptidase in the renin-angiotensin system (RAS). On thyroid follicular cells, ACE2R allows SARS-CoV-2 to invade the thyroid gland, impose cytopathic effects and produce endocrine abnormalities, including stiff back, neck pain, muscle ache, lethargy, and enlarged, inflamed thyroid gland in COVID-19 patients. Further damage is perpetuated by the sudden bursts of pro-inflammatory cytokines, which is suggestive of a life-threatening syndrome known as a "cytokine storm". IL-1β, IL-6, IFN-γ, and TNF-α are identified as the key orchestrators of the cytokine storm. These inflammatory mediators upregulate transcriptional turnover of nuclear factor-kappa B (NF-κB), Janus kinase/signal transducer and activator of transcription (JAK/STAT), and mitogen-activated protein kinase (MAPK), paving the pathway for cytokine storm-induced thyroid dysfunctions including euthyroid sick syndrome, autoimmune thyroid diseases, and thyrotoxicosis in COVID-19 patients. Targeted therapies with corticosteroids (dexamethasone), JAK inhibitor (baricitinib), nucleotide analogue (remdesivir) and N-acetyl-cysteine have demonstrated effectiveness in terms of attenuating the severity and frequency of cytokine storm-induced thyroid dysfunctions, morbidity and mortality in severe COVID-19 patients. Here, we review the pathogenesis of cytokine storms and the mechanisms and pathways that establish the connection between thyroid disorder and COVID-19. Moreover, cross-talk interactions of signalling pathways and therapeutic strategies to address COVID-19-associated thyroid diseases are also discussed herein.
The invention provides a near-infrared long-afterglow luminescent material excited by a biological window and a preparation method thereof, wherein the chemical structural formula of the material is as follows: zn  1+x  Ga  2‑2x  Sn  x  O  4  :Cr  y  ，Y  z  . Wherein x is more than 0 and less than or equal to 0.5,0 and more than y is more than 0.01,0 and less than or equal to z is less than 0.01. The excitation light of the near-infrared long-afterglow luminescent material is positioned at a biological imaging window, and the wavelength of the excitation light is more than 650nm. And the luminous peak value is about 696nm, the long afterglow luminous time is far more than 1 hour, the afterglow intensity is strong, the afterglow time is long, and the long afterglow luminous material can be used in the fields of photodynamic therapy, biological imaging and the like. In addition, the invention also relates to a preparation method of the near-infrared long-afterglow luminescent material excited by the biological window, and the raw materials are widely available and have low price. In the operation process, only the compounds need to be mixed, ground and calcined, and a protective atmosphere is not needed, so that the operation is simple, and the method is suitable for large-scale production.
Labels and methods are provided for detecting deposits, including drusen, sub-retinal deposits, basal laminar and linear deposits, and the like. The labels can detect the presence, progression, or regression of hydroxyapatite, which can be indicative of the presence or the potential to develop such deposits. The labels can include a conjugate comprising a hydroxyapatite binding moiety and a label moiety, which can provide a detectable signal upon binding of the conjugate to hydroxyapatite. The labels and methods can be utilized to detect deposits in eye tissue, such as the retina, brain tissue, or the like. Methods are also provided for utilizing the present labels to predict or diagnose a neurodegenerative disease, including age-related macular degeneration. Accordingly, some methods can predict or diagnose age-related macular degeneration, including early signs or advanced forms thereof, based on the presence of hydroxyapatite in a tissue sample obtained from a subject.
A patient identification and vitals screening device for rapid identification and vitals screening of a patient includes a fingerprint scanner and a pulse oximeter, which are attached to a housing that defines an interior space. The fingerprint scanner generates a fingerprint scan from a finger of a patient that is positioned upon the fingerprint scanner so that the patient can be identified. The pulse oximeter is positioned within the fingerprint scanner and measures a pulse rate and a blood oxygen level of the patient. The patient identification and vitals screening device can be engaged to an electronic device that is in possession of a healthcare worker. The electronic device is engaged to a server upon which a plurality of fingerprint scans and a plurality of healthcare records is positioned. The server identifies the patient and presents their healthcare record to the healthcare worker.
The invention provides a grape polyphenol microcapsule health care product. The grape polyphenol microcapsule health care product comprises grape polyphenols, sodium alginate, calcium chloride, chitosan and corn porous starch in the mass ratio of (1.25-3.75): (6-12): 25: 5: (5-15), wherein the grape polyphenols comprise 30-70% of grape skin polyphenols and 70-30% of grape seed polyphenols. As a functional health care product, the grape polyphenol microcapsule health care product has a variety of biological activities, such as anti-oxidation, anti-free radical injuries and anti-radiation activities, as well as the activities of protecting cardiovascular vessels and the like. By preparing the grape polyphenol microcapsule health care product into a microcapsule, the anti-oxidation capability of the grape polyphenols can be protected to the greatest extent. The grape polyphenol microcapsule health care product is simple in preparation method; and by adding the corn porous starch in the preparation process of the grape polyphenol microcapsule, the embedding rate of the grape polyphenols is improved, the release time is effectively controlled, the slow release effect is increased at the same time, and the maximization of the health care function of the grape polyphenols is realized. As the grape polyphenols are rich in grape skins and seeds for making wine, the development of comprehensive utilization of the grape skins and the seeds for making the wine has good economic benefits and environment-friendly benefits.
Participants in The EXER-only group will be group-based, and offered weekly for about 60 minutes during the execution phase (a total 20 sessions from weeks 4-24). The combination of resistance and aerobic exercises can improve muscle quantity and strength as well as reduce body fat in people with sarcopenic obesity, and will be adopted in this study.
Kinesio taping was applied 2 times a week for 3 weeks to the KT group. KT improves fluid movement by widening the distance between connective tissues like skin and fascia,fascia and muscles and skin and muscles.
All participants will receive a one-time administration of SMS001 undergoing their scheduled lung cancer surgery. Participants are given SMS001 and are watched very closely for side effects. If the side effects are manageable, then more participants are asked to join the study and are given a higher dose of SMS001, until a pre-defined suitable dose is reached.
The present invention belongs to the field of biomedicine preparing technology.  On the basis of patent "the purifying and utilizing of distiller's residue", Fengweigu mushroom NF1 strain is screened and cultured in distiller's residue culture medium.  By means of deep liquid fermentation to obtain fermented liquid, and the fermented liquid is separated and purified to obtain NF1 polysaccharide.  The NF1 polysaccharide is sulfonated into sulfonated NF1 polysaccharide, which is further capsulized to form anti-AIDS medicine.  LD50 acute toxicity test result is 10007 mg/kg, and extracorporeal detection proves its HIV-RT inhibiting rate of 94.02 %.  Orally taking probes its AIDS treating effect.
Aims: To develop an internet-based support and coaching model for young people with autism spectrum disorder (ASD) and/or attention-deficit/hyperactivity disorder (ADHD), and to validate the model. Method: A user centred design was applied to develop a model for internet-based support and coaching, where individuals received eight-week support via internet (chat). The model was validated by ten individuals, 15 to 26 years of age, with ASD and/or ADHD. Self-report questionnaires (Sense of Coherence (SOC), the Rosenberg Self Esteem Scale, the Manchester Short Assessment of Quality of Life (MANSA), Montgomery Åsberg Depression Rating Scale (MADRS), and the Hospital Anxiety and Depression Scale (HAD)) were distributed before and after intervention. A structured interview regarding the quality of the model, the Patient perspective of Care and Rehabilitation process (POCR), was used after the intervention. Results: The validation showed significant improvement of SOC, self-esteem and subjective Quality of Life at follow-up and the majority perceived high fulfilment/importance on the POCR. Conclusions: The model can be an important complement to other interventions for young people with ASD and/or ADHD.
Undernourishment is a persistent public health problem contributing to increased mortality in children under five in low-income countries, likely exacerbated by socio-economic disparities within communities. This paper aimed to examine the effect of wealth-related inequality on undernutrition in children under five in low, lower-middle, and upper-middle-income countries (LMICs). We analyzed cross-sectional data from the demographic and health survey program collected between 2017 and 2022 from 24 LMICs. Children born within 5 years preceding the survey were included in the analysis. Child undernutrition was the dependent variable (measured by stunting, wasting, and underweight) and country-level wealth-based inequality was the independent variable assessed by concentration index values stratified by the World Bank's income categories. Within country inequality of child undernutrition was determined by concentration index (C) values with 95% confidence intervals (95% CI) and sub-group analysis by place of residence and sex of the child. We then fit bootstrapped meta-regression to check the variation in inequality of child undernutrition across different income category countries. The analysis was controlled by potential confounding variables. From the total sample size of 334,502 children included in the study, 35% were undernourished. Wealth-related inequality in child undernutrition was observed in 11 countries, consistently across income categories. Child undernutrition was highly concentrated among the poor households of Türkiye [C: - 0.26, 95% CI - 0.31 to - 0.20], and Cameroon [C: - 0.19, 95% CI - 0.22 to - 0.17], and relatively it was less concentrated among the poor in Liberia [C: - 0.07, 95% CI - 0.11 to - 0.04], and Gambia [C: - 0.07, 95% CI - 0.11 to - 0.04]. There is no difference in undernutrition associated with inequality between the three broad LMIC categories. The wealth-related inequality in child undernutrition within many of the included countries is still very significant. However, the economic category of countries made no difference in explaining wealth-related inequality in child undernutrition. Inter-sectoral collaboration to fight poverty and render special attention to the disadvantaged population segments would potentially help to address the observed inequity.
The risk of sudden cardiac death (SCD) in patients with cancer receiving cancer therapies is not well defined. In this study we aimed to (1) evaluate the risk of SCD during the first 6 months of cancer treatment and (2) identify risk factors (RFs) for SCD in patients who underwent active cancer treatment. The study population comprised 8,356 patients who received any cancer treatment at the University of Rochester Medical Center from 2011 to 2020. The primary end point was the occurrence of SCD within 6 months of cancer treatment. SCD was defined by using the modified Hinkle-Thaler classification. The mean age at the time of cancer treatment was 64 ± 14 years and 49% were women. All-cause mortality occurred in 834 patients (10%), of whom 51 (6%) were identified as SCD. The cumulative probability of SCD at 6 months was 0.6%. Age <74 years (0.042), history of congestive heart failure (0.058) and lung cancer (0.004) were identified as independent RFs for SCD in the multivariate Cox regression models. The cumulative probability of SCD at 6 months from cancer treatment initiation was significantly higher in patients with ≥2 RFs (1.6%) than in patients with 0 or 1 RF (0.5%) (log-rank p <0.001). In conclusion, our findings suggest that active cancer treatment is associated with SCD risk that is more pronounced in younger patients (< 74 years), patients with cancer and a history of heart failure, and those who underwent treatment for lung cancer. Future studies should address appropriate modalities for prevention and protection in this high-risk population.
Participants randomized to the coaching group will receive a 1-hour initial professional coaching session followed by five 30-minute professional coaching sessions occurring at a goal frequency of every 2 to 3 weeks within 5 months (total of 3.5 coaching hours). All coaching sessions will be conducted individually (i.e. between one coach and one participant). Participants will be able to request coaching on any topic to individualize the intervention, but the general structure of the sessions will be standardized across participants. All coaching sessions will be performed over the phone or virtual web meeting as standard in coaching practices.